Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
NCT05842707
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
Interventions
DRUG:
dualCAR-NK19/70 cell
Sponsor
Aibin Liang，MD，Ph.D.